Abstract:Objective:To investigate the influence factors of allograft acute rejection (AR) at the metaphase and long-term after kidney transplantation and the postoperative survival of allograft.Methods:The clinical data were retrospectively analysed in 43 recipients who accepted kidney transplantation were more than 1 years and were diagnosed with AR by allograft renal biopsy during January 2018 to December 2019. Seventeen of them with acute antibody-mediated rejection were as acute antibody rejection group, 26 of them with acute T cell-mediated rejection were as acute T cell rejection group, and 39 recipients who got kidney transplantation during the same period (in 2 weeks) were matched as control group. Paired sample t test or one-way ANOVA was used to compare the measurement data conforming to normal distribution among multiple groups. Chi-square test or Fisher exact probability was used for comparison between counting data groups. Kaplan-Meier was used for survival analysis and log-rank was used for comparison. A P<0.05 was considered statistically significant.Results:The proportion of 2 mismatches at HLA-A sites in HLA match before operation (4/17) was more higher in acute antibody rejection group than that in control group (1/39), and the difference was statistically significant (P=0.026). Serum creatinine and estimated glomerular filtration rate (eGFR) at the onset and last time of AR were higher in acute antibody rejection group and acute T cell rejection group than those before AR (all P<0.05). Serum creatinine and eGFR at the onset and last time of AR in acute antibody rejection and acute T cell rejection group were higher than those in control group (all P<0.05). The proportion of chronic kidney disease (CKD)-4 recipients in acute antibody rejection group was lower than that in acute T cell rejection group (χ2=5.73, P<0.05). The proportion of CKD-4 recipients in acute T cell rejection group and the proportion of renal allograft failure in acute antibody rejection group were higher than those in control group (χ2=17. 727 and 9.882, all P<0.05). When AR happened, the rate of PRA-Ⅰ positive recipients [41.2% (7/17)] and the rate of PRA-Ⅱ positive recipients [88.2% (15/17)] in acute antibody rejection group were both higher than those in acute T cell rejection group [11.5% (3/26) and 26.9% (7/26), respectively], the difference had statistical significance (P=0.042, P<0.001). The serum concentration of tacrolimus was significantly decreased in the acute antibody rejection group (3.72±0.76) ng/mL and in the acute T cell rejection group (3.37±0. 86) ng/mL when the AR occurred, which were all lower than that of the control group (5.73±1.25) ng/mL, the difference had statistical significance (all P<0.05), and also lower than the serum concentration of tacrolimus before AR occurred, the difference had statistical significance (t=7.120 and 6.216, all P<0.05). There were 4 recipients in the acute T cell rejection group used cyclosporine, and the serum concentration of cyclosporine of 3 recipients among them was not up to the mark at 33 (112.4 ng/mL), 36 (138.3 ng/mL) and 55 (7.0 ng/mL) months after transplantation. The serum concentration of cyclosporine of 2 recipients who used cyclosporine in the acute T cell rejection group was 43.2 (16 months after transplantation) and 24.6 ng/mL (177 months after transplantation), which were not up to the mark. All the recipients were followed up until June 30, 2021, the survival rate of transplant kidney of the acute antibody rejection group was lower than the control group (χ2=8.738, P<0.05).Conclusions:Mismatch at the HLA-A sites and the lower serum concentration of tacrolimus were the important factors for inducing AR in the metaphase and long-term after kidney transplantation. Acute antibody-mediated rejection was the important factor that affected the survival of transplant kidney.

Application of OKT3 in the Prevention and Treatment of Acute Rejection for Kidney Recipients

OKT3 for treatment of rejection in renal transplantation

Clinical Study of Single-Dose of Recombinant Humanized Anti-Cd3 Monoclonal Antibody Injection in Kidney Transplant Recipients

OKT3 for induction of immunosuppression in renal transplantation

OKT 3 for rejection reversal in pediatric renal transplantation

OKT3 for induction of immunosuppression and treatment of rejection in cardiac allograft recipients

Clinical experience with OKT3 monoclonal antibody for treatment of acute renal allograft rejection based on sequential histological evaluation

Clinical application of monoclonal/polyclonal antibody in posttransplant patients with acute rejection

Treatment of severe rejection of kidney transplants with Orthoclone OKT3

The use of OKT3 in recipients of pancreatic, pulmonary, and bone marrow allografts

Application of Mycophenolate Mofetil Combined with Low-Dose Tacrolimus and Corticosteroid Regimen after Renal Transplantation

Clinical study on allograft acute rejection at metaphase and long-term after kidney transplantation

Human in vivo antigenic modulation of T lymphocytes induced by OKT3 for preventi on of transplant rejection

Advances in the Treatment of Acute and Chronic Rejection for Vascularized Organ Allografts

Effect of acute humoral rejection on renal allograft survival

IMPACT OF PRE-TRANSPLANT SERUM LEVELS OF IP-10,MIG AND BLC ON ACUTE REJECTION EPISODE

Low-dose and short-term antithymocyte globulin in treatment of steroid-resistant rejection after renal transplantation

Mycophenolate mofetil for prevention and treatment of rejection of the graft and its safety in renal transplant recipients

Application of Mycophenolate Mofetil in Prevention of Acute Renal Transplantation Rejection in the Near Period of Postoperation

Standard versus low‐dose OKT3 induction therapy of cadaveric renal transplants: Comparison of outcome data versus OKT3 dose and serum levels

Pre-transplant Impact Factors of Acute Rejection after Kidney Transplantation